117 Kendrick Street
Tel: (718) 292-4200
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a clinical-stage biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our team is anchored by core values of character, urgency, respect and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. At Verastem, we believe that empowering employees is what makes them truly care about the important work they do.
293 articles with Verastem Oncology
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma
Verastem, Inc. announced an oral presentation highlighting supportive Phase 1 clinical data for duvelisib in patients with relapsed or refractory peripheral T-cell lymphoma at the 2019 International Conference on Malignant Lymphoma being held June 18-22, 2019, in Lugano, Switzerland.
6/21/2019Biotech and pharma companies strengthen their leadership teams and committees with new appointments.
Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Robert Forrester has decided to step down as President and Chief Executive Officer. Mr. Forrester has agreed to continue serving Verastem Oncology in an advisory capacity.
Chief Operating Officer Dan Paterson has been appointed to the role of president and will lead the company while the board of directors conducts a search for a new CEO.
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting
In CLL/SLL Patients in the DUO Study, Duvelisib Treatment Rapidly Increased Lymphocytes and Resulted in Shrinkage of Lymph Nodes, With 86% of Patients Achieving a Lymph Node Response
Verastem, Inc. announced that the Company will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 11:30 a.m. EDT in New York, NY.
Verastem, Inc. announced that the Company will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Thursday, May 23, 2019 at 1:30 p.m. PDT in Beverly Hills, CA.
Verastem Oncology to Present New COPIKTRA™ (Duvelisib) Dose Modification Data from Patients Treated in the Phase 3 DUO Study
Verastem, Inc. announced a poster highlighting dose modification data from the Phase 3 DUO study evaluating COPIKTRA (duvelisib) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies.
Verastem, Inc. reported financial results for the three months ended March 31, 2019.
New Terms Provide for Lower Interest Rate and Longer Interest-Only Payment Period
Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced the grant of options to purchase 112,000 shares of its common stock to four new employees.
Verastem, Inc. announced that the Company will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 11:50 a.m. BST in London, UK.
Verastem, Inc., focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, announced that the Company will present at the following upcoming investor conferences
Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Malignancies
DUO™ Crossover Extension Study Demonstrates 77% ORR and Median PFS of 15 Months in Patients with Relapsed or Refractory CLL/SLL Who Had Experienced Disease Progression Following Ofatumumab Monotherapy; Achieves 80% ORR in Patients with 17p Deletion
Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) in Patients with CLL/SLL Who Have Progressed Following Two Prior Lines of Therapy
COPIKTRA Demonstrates Progression-Free Survival of 16.4 Months and an Overall Response Rate of 78% in Adult Patients with CLL/SLL After At Least Two Prior Therapies
Verastem, Inc. announced the grant of options to purchase 239,000 shares of its common stock to eight new employees and 50,000 restricted stock units to one new employee.
Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019
Verastem, Inc. announced that the Company will host a conference call and webcast on Tuesday, March 12, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2018.
2/22/2019Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more.
Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced that the Company will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:30 a.m. EST in New York, NY.
Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced several key appointments to its management team.